Literature DB >> 36147762

Intrathecal Methotrexate Toxicity Resulting in Brain Death due to Generalized Cerebral Edema Case Report.

Haoming Pang1, Julie L Chan1, Serguei I Bannykh2, Michael Gezalian1, Shouri Lahiri1, Shahed Toossi1, Maranatha Ayodele1.   

Abstract

Intrathecal methotrexate (IT MTX) resulting in severe adverse events including life-threatening cerebral edema is not well described. We report a rare case of death in a 37-year-old BRCA1+ woman with metastatic triple-negative breast cancer status post mastectomy following administration of IT MTX for leptomeningeal carcinomatosis. Within the 24 hours after intraoperative IT MTX delivery, she developed neurologically devastating diffuse cerebral edema leading to uncal and cerebellar tonsillar herniation. This case report highlights a rare but devastating side effect of IT MTX.
© The Author(s) 2022.

Entities:  

Keywords:  breast cancer; carcinomatosis; case report; cerebral edema; intrathecal methotrexate

Year:  2022        PMID： 36147762      PMCID： PMC9485701          DOI： 10.1177/19418744221106313

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN： 1941-8744


  17 in total

1.  The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study.

Authors:  W Boogerd; M J van den Bent; P J Koehler; J J Heimans; J J van der Sande; N K Aaronson; A A M Hart; J Benraadt; Ch J Vecht
Journal:  Eur J Cancer       Date:  2004-12       Impact factor: 9.162

2.  111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases.

Authors:  W P Mason; S D Yeh; L M DeAngelis
Journal:  Neurology       Date:  1998-02       Impact factor: 9.910

Review 3.  Leptomeningeal carcinomatosis.

Authors:  S A Grossman; M J Krabak
Journal:  Cancer Treat Rev       Date:  1999-04       Impact factor: 12.111

4.  Acute tumor lysis syndrome after intrathecal methotrexate administration.

Authors:  E D Simmons; K A Somberg
Journal:  Cancer       Date:  1991-04-15       Impact factor: 6.860

5.  Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis.

Authors:  M L Tetef; K A Margolin; J H Doroshow; S Akman; L A Leong; R J Morgan; J W Raschko; N Slatkin; G Somlo; J A Longmate; M I Carroll; E M Newman
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

6.  Severe complications after intrathecal methotrexate (MTX) for treatment of primary central nervous system lymphoma (PCNSL).

Authors:  Ralf Weigel; Pascal Senn; Joachim Weis; Joachim K Krauss
Journal:  Clin Neurol Neurosurg       Date:  2004-03       Impact factor: 1.876

7.  Intracranial tumor lysis and cerebral edema after administration of intrathecal methotrexate: a case report and discussion.

Authors:  Lohith S Bachegowda; Petros D Grivas; Rachna Anand; Elissa Stecker; Kristine Ward
Journal:  Med Oncol       Date:  2009-10-22       Impact factor: 3.064

8.  Meningeal carcinomatosis in breast cancer.

Authors:  H Y Yap; B S Yap; C K Tashima; A DiStefano; G R Blumenschein
Journal:  Cancer       Date:  1978-07       Impact factor: 6.860

9.  Association Between Anesthesia Exposure and Neurocognitive and Neuroimaging Outcomes in Long-term Survivors of Childhood Acute Lymphoblastic Leukemia.

Authors:  Pia Banerjee; Michael G Rossi; Doralina L Anghelescu; Wei Liu; Ashley M Breazeale; Wilburn E Reddick; John O Glass; Nicholas S Phillips; Lisa M Jacola; Noah D Sabin; Hiroto Inaba; Deokumar Srivastava; Leslie L Robison; Ching-Hon Pui; Melissa M Hudson; Kevin R Krull
Journal:  JAMA Oncol       Date:  2019-10-01       Impact factor: 31.777

10.  Subacute neurological deficits and respiratory insufficiency due to intrathecal methotrexate.

Authors:  Sjoerd I P J de Faber; Pim G N J Mutsaers; Martin J van den Bent; Matthijs van der Meulen
Journal:  J Clin Transl Res       Date:  2021-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.